Inflammatory bowel diseases (IBDs) may result from mutations in genes encoding for innate immunity, which can lead to exacerbated inflammatory response. Although some mono-targeted treatments have developed in recent years, IBDs are caused through several pathway perturbations. Therefore, targeting all these pathways is difficult to be achieved by a single agent. Moreover, those mono-targeted therapies are usually expensive and may cause side-effects. These limitations highlight the significance of an available, inexpensive and multi-targeted dietary agents or natural compounds for the treatment and prevention of IBDs. Curcumin is a multifunctional phenolic compound that is known for its anti-inflammatory and immunomodulatory properties. Over the past decades, mounting experimental investigations have revealed the therapeutic potential of curcumin against a broad spectrum of inflammatory diseases including IBDs. Furthermore, it has been reported that curcumin directly interacts with many signaling mediators implicated in the pathogenesis of IBDs. These preclinical findings have created a solid basis for the assessment of the efficacy of curcumin in clinical practice. In clinical trials, different dosages e.g., 550 mg /three times daily-1month, and 1 g /twice times daily-6month of curcumin were used for patients with IBDs. Taken together, these findings indicated that curcumin could be employed as a therapeutic candidate in the treatment of IBDs. Moreover, it seems that overcome to current limitations of curcumin i.e., poor oral bioavailability, and poor oral absorption with using nanotechnology and others, could improve the efficacy of curcumin both in pre-clinical and clinical studies.

炎症性肠病（IBD）可能是由于先天免疫性编码基因的突变导致的，这可能导致炎症反应加剧。尽管近年来已经开发了一些单靶标治疗方法，但IBD是通过几种途径的扰动引起的。因此，单一药剂难以实现靶向所有这些途径。而且，那些单靶标疗法通常是昂贵的并且可能引起副作用。这些局限性凸显了可利用的，廉价的和多目标饮食剂或天然化合物对IBD的治疗和预防的重要性。姜黄素是一种多功能酚类化合物，以其抗炎和免疫调节特性而闻名。在过去的几十年中，越来越多的实验研究表明姜黄素对包括IBD在内的多种炎症疾病的治疗潜力。此外，已经报道姜黄素直接与许多与IBD的发病机理有关的信号传导介质相互作用。这些临床前发现为评估姜黄素在临床实践中的疗效奠定了坚实的基础。在临床试验中，不同剂量例如，对于IBD患者，使用姜黄素每天550毫克/每天3次，每月3次1次/两次，姜黄素6个月。综上所述，这些发现表明姜黄素可以用作IBD治疗中的候选治疗药物。而且，似乎克服了姜黄素目前的局限性，即使用纳米技术和其他技术克服了口服姜黄素不良的口服生物利用度和不良的口服吸收，可以改善姜黄素在临床前和临床研究中的功效。